USA flag logo/image

An Official Website of the United States Government

Nanodroplet PCR Lab-Chip for Clinical Pathogen Detection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75885
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI065169
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
ADVANCED LIQUID LOGIC
615 Davis Dr., Suite 800 PO Box 14025 RESEARCH TRIANGLE PARK, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Nanodroplet PCR Lab-Chip for Clinical Pathogen Detection
Agency: HHS
Contract: 2R44AI065169-02A2
Award Amount: $2,957,902.00
 

Abstract:

DESCRIPTION (provided by applicant): It is estimated that 2 million health-care associated infections are acquired each year by hospitalized patients resulting in 90,000 deaths and about 4.5 billion in excess health care costs. A large and growing percent age of these infections can be attributed to Staphylococcus aureus and, in particular, to methicillin-resistant S. aureus (MRSA). Rapid PCR-based tests have been developed for screening MRSA in health-care settings, but the high cost and complexity of exis ting nucleic acid testing platforms have limited their acceptance for routine screening in most health-care settings. The goal of this project is to develop a rapid, low-cost, easy-to-use nucleic acid testing platform that can be deployed for MRSA screenin g in a wide range of health-care settings. The proposed testing platform is based on Advanced Liquid Logic's digital microfluidics technology which enables programmable micro-manipulation of sub-microliter sized droplets using an electrode array formed o n a low-cost and disposable printed circuit board substrate. In Phase I of this project Advanced Liquid Logic developed chip-based methods for rapid thermocycling, real-time PCR detection, magnetic-bead based sample preparation, and reaction preparation an d mixing. In Phase II, these results will serve as the foundation for the development of a product prototype nucleic acid analysis system for near-patient and point-of-care use. An MRSA screening test will be developed on the platform and extensively valid ated in preparation for an FDA submission. Ultimately, additional cartridges could be developed for screening and detection of other health-care associated infections. This lab-on-a-chip platform will offer significant advantages over other approaches in t erms of flexibility, scalability, performance and cost. PUBLIC HEALTH RELEVANCE: A system for the detection of methicillin-resistant Staphylococcus aureus will be developed to help control the spread of antibiotic-resistant bacteria in hospital sett ings.

Principal Investigator:

Michael G. Pollack
9192879010
MGP@LIQUID-LOGIC.COM

Business Contact:

Richard M. West
information@liquid-logic.com
Small Business Information at Submission:

ADVANCED LIQUID LOGIC
ADVANCED LIQUID LOGIC 615 Davis Dr., Suite 800 RESEARCH TRIANGLE PARK, NC -

EIN/Tax ID: 120170896
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No